sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Diabetic Kidney Disease Market Size Study, by Drug Class, by Route of Administration, by Distribution Channel, and Regional Forecasts 2024-2032

Global Diabetic Kidney Disease Market Size Study, by Drug Class,...

Home / Categories / Healthcare
Global Diabetic Kidney Disease Market Size Study, by Drug Class, by Route of Administration, by Distribution Channel, and Regional Forecasts 2024-2032
Global Diabetic Kidney Disease Market...
Report Code
RO1/103/3173

Publish Date
07/Oct/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global diabetic kidney disease market is valued at approximately USD 2.89 billion in 2023 and is anticipated to grow at a steady CAGR of 4.8% over the forecast period from 2024 to 2032, reaching a projected market size of USD 4.21 billion by 2032. Diabetic kidney disease, a severe complication of diabetes, occurs when high blood sugar levels cause damage to the kidneys' blood vessels. This leads to impaired kidney function, resulting in the accumulation of waste in the body and potentially severe health issues. As the prevalence of diabetes continues to rise globally, the diabetic kidney disease market is witnessing significant growth, driven by the increasing awareness of the disease, the availability of advanced treatment options, and developments in diagnostic tools and renal replacement therapies.

The market's growth is primarily fueled by the sharp increase in the global diabetic population, which correlates with a higher incidence of diabetic kidney disease. As lifestyle habits change and physical activity decreases, more individuals are being diagnosed with diabetes, elevating their risk of developing kidney complications. The aging global population further exacerbates this trend, as older individuals are more susceptible to chronic conditions, including diabetic kidney disease, due to long-standing diabetes. Healthcare systems are now faced with the challenge of managing this growing burden, which is driving the demand for effective treatments and early diagnostic tools.

However, the market faces several challenges, including the high cost of treatment devices and a lack of awareness in low-income regions. These barriers can limit access to care, especially in developing countries where healthcare resources are limited. Despite these challenges, the market presents lucrative opportunities, particularly in regions experiencing rapid economic growth and urbanization, such as Asia-Pacific and Latin America. The rising prevalence of diabetes in these regions, coupled with increased healthcare spending, is expected to drive market expansion over the forecast period.

North America has been the dominant region in the global diabetic kidney disease market, with the U.S. holding the largest share due to its high prevalence of diabetes and access to advanced healthcare. The region's economic capabilities and well-developed healthcare infrastructure have led to significant investments in research and development, resulting in innovative treatments and early adoption of new therapies. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, increasing awareness of diabetes-related complications, and the availability of affordable generic drugs.

Major market players included in this report are:
AstraZeneca
Boehringer Ingelheim
Janssen Pharmaceuticals
Bristol Myers Squibb
GSK
Novo Nordisk
Eli Lilly and Company
Merck & Co.
Sanofi
AbbVie
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Lupin
Aurobindo Pharma
Takeda Pharmaceutical Company Limited
The detailed segments and sub-segment of the market are explained below:
By Drug Class
Angiotensin Receptor Blockers (ARBs)
Calcium Channel Blockers
Antioxidant Inflammation Modulator
Angiotensin-Converting Enzyme (ACE) Inhibitors
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2031.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com